Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
8,821,889
-
Share change
-
+4,732,186
-
Total reported value
-
$39,349,366
-
Put/Call ratio
-
133%
-
Price per share
-
$4.46
-
Number of holders
-
36
-
Value change
-
+$21,195,496
-
Number of buys
-
26
-
Number of sells
-
7
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q1 2021
As of 31 Mar 2021,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
36 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,821,889 shares.
The largest 10 holders included
Psagot Investment House Ltd., Burrage Capital Management LLC, DAFNA Capital Management LLC, RENAISSANCE TECHNOLOGIES LLC, UBS OCONNOR LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Phoenix Holdings Ltd., SUSQUEHANNA INTERNATIONAL GROUP, LLP, D.A. DAVIDSON & CO., and ADVISOR GROUP HOLDINGS, INC..
This page lists
36
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.